Couverture de Therapeutic Momentum: Bench to Bedside Chats

Therapeutic Momentum: Bench to Bedside Chats

Therapeutic Momentum: Bench to Bedside Chats

De : Therapeutic Momentum
Écouter gratuitement

À propos de ce contenu audio

 Podcast by Therapeutic MomentumAll rights reserved Science
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Robert Plenge - Finding Truth & Making Medicines

      Robert Plenge - Finding Truth & Making Medicines
      Jan 21 2026
      Robert Plenge is a physician-scientist known for translating human genetics into drug discovery insights. On his well known blog, he writes with inspiring clarity about genomics, therapeutic target validation, and lessons from translational research, bridging academic rigor and industry practice for scientists and clinicians alike. In this interview we explore Robert's passion for causal human biology, drug development and leading teams. Roberts Blog: https://www.robertplenge.com
      Afficher plus Afficher moins
      1 h
    • Andy Plump - Translational Roles & Global Perspectives

      Andy Plump - Translational Roles & Global Perspectives
      Mar 28 2025
      Andy Plump discusses his journey from a postdoc at UCSF to a leading roles in pharmaceutical research. Andy, who joined Merck in 2001, worked in clinical pharmacology. He highlighted the importance of genetics in target selection and shares his experiences at Sanofi and Takeda, emphasizing the cultural sensitivities and leadership lessons gained from global experiences. The interview explores the transformative potential of AI and machine learning in biopharmaceutical research. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
      Afficher plus Afficher moins
      45 min
    • Mathai Mammen - Motivated by Math, Medicine & Memories

      Mathai Mammen - Motivated by Math, Medicine & Memories
      Mar 28 2025
      Mathai Mammen is a world-renowned innovator in drug discovery, development, and team- and company-building responsible for creating 13 transformational medicines from discovery through commercial launch and more than 25 other potential medicines that have achieved clinical proof-of-concept, many of these practice-changing. Mathai is the CEO, President and Chairman of Cambridge-based Parabilis Medicines, a clinical-stage biopharmaceutical company advancing a new category of peptide therapeutics for people affected by cancer and other severe diseases. Previously Mathai was Executive Vice President of Pharmaceuticals, R&D at Johnson & Johnson, one of the largest R&D organizations in the world. Prior to that Mathai was the leader of much of the research at Merck including Oncology, Immunology and Cardiovascular Disease. He began his career as head of R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides, which split to form Theravance Biopharma and Innoviva. Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.
      Afficher plus Afficher moins
      1 h et 8 min
    Aucun commentaire pour le moment